Biotechnology company Moderna Inc (Nasdaq:MRNA) revealed on Thursday that it has dosed the first participant under its Phase 1/2 study of its vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co Ltd.
TAK-919 is reportedly Takeda's development code for Moderna's COVID-19 vaccine candidate.
This placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
In conjunction, Takeda plans to enrol 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 μg dose at both vaccinations. Participants will be followed through 12 months after the second vaccination.
Under the terms of the prior agreement, Takeda will import and distribute 50m doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease